The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

被引:53
作者
Fecteau, Heather [1 ]
Vogel, Kristen J. [2 ]
Hanson, Kristen [3 ]
Morrill-Cornelius, Shannon [4 ]
机构
[1] Med Ctr Plano, Dallas, TX 75075 USA
[2] North Shore Univ Hlth Syst, Evanston, IL USA
[3] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA
[4] Danbury Hosp, Danbury, CT USA
关键词
Genetic counseling; Neoplastic syndromes; Hereditary; Genetics; Medical; Next generation sequencing; Genetic testing panels; P53 GERMLINE MUTATIONS; LI-FRAUMENI SYNDROME; SUSCEPTIBILITY; BREAST; OVARIAN; STATEMENT; CARRIERS; BRIP1; PALB2;
D O I
10.1007/s10897-014-9714-7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cancer genetics professionals face a new opportunity and challenge in adapting to the availability of cancer genetic testing panels, now available as a result of Next Generation Sequencing (NGS) technology. While cancer panels have been available for over a year, we believe that there is not yet enough data to create practice guidelines. Despite this, a year of experience allows us to provide our opinion on points to consider as cancer genetic counselors incorporate this testing technology into genetic counseling practice models. NGS technology offers the ability to potentially diagnose hereditary cancer syndromes more efficiently by testing many genes at once for a fraction of what it would cost to test each gene individually. However, there are limitations and additional risks to consider with these tests. Obtaining informed consent for concurrent testing of multiple genes requires that genetics professionals modify their discussions with patients regarding the potential cancer risks and the associated implications to medical management. We propose dividing the genes on each panel into categories that vary by degree of cancer risk (e.g. penetrance of the syndrome) and availability of management guidelines, with the aim to improve patient understanding of the range of information that can come from this testing. The increased risk for identifying variants of uncertain significance (VUS) when testing many genes at once must be discussed with patients. Pretest genetic counseling must also include the possibility to receive unexpected results as well as the potential to receive a result in the absence of related medical management guidelines. It is also important to consider whether a single gene test remains the best testing option for some patients. As panels expand, it is important that documentation reflects exactly which genes have been analyzed for each patient. While this technology holds the promise of more efficient diagnosis for many of our patients, it also comes with new challenges that we must recognize and address.
引用
收藏
页码:633 / 639
页数:7
相关论文
共 29 条
[1]  
Ackerman MJ, 2011, HEART RHYTHM, V8, P1308, DOI [10.1016/j.hrthm.2011.05.020, 10.1093/europace/eur245]
[2]   Relative frequency and morphology of cancers in carriers of germline TP53 mutations [J].
Birch, JM ;
Alston, RD ;
McNally, RJQ ;
Evans, DGR ;
Kelsey, AM ;
Harris, M ;
Eden, OB ;
Varley, JM .
ONCOGENE, 2001, 20 (34) :4621-4628
[3]   Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer [J].
Casadei, Silvia ;
Norquist, Barbara M. ;
Walsh, Tom ;
Stray, Sunday ;
Mandell, Jessica B. ;
Lee, Ming K. ;
Stamatoyannopoulos, John A. ;
King, Mary-Claire .
CANCER RESEARCH, 2011, 71 (06) :2222-2229
[4]  
Chompret A, 2000, BRIT J CANCER, V82, P1932
[5]   Genetic variants of uncertain significance: Flies in the ointment [J].
Domchek, Susan ;
Weber, Barbara L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :16-17
[6]   Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net? [J].
Domchek, Susan M. ;
Bradbury, Angela ;
Garber, Judy E. ;
Offit, Kenneth ;
Robson, Mark E. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1267-1270
[7]   A recurrent mutation in PALB2 in Finnish cancer families [J].
Erkko, Hannele ;
Xia, Bing ;
Nikkilae, Jenni ;
Schleutker, Johanna ;
Syrjaekoski, Kirsi ;
Mannermaa, Arto ;
Kallioniemi, Anne ;
Pylkas, Katri ;
Karppinen, Sanna-Maria ;
Rapakko, Katrin ;
Miron, Alexander ;
Sheng, Qing ;
Li, Guilan ;
Mattila, Henna ;
Bell, Daphne W. ;
Haber, Daniel A. ;
Grip, Mervi ;
Reiman, Mervi ;
Jukkola-Vuorinen, Arja ;
Mustonen, Aki ;
Kere, Juha ;
Aaltonen, Lauri A. ;
Kosma, Veli-Matti ;
Kataja, Vesa ;
Soini, Ylermi ;
Drapkin, Ronny I. ;
Livingston, David M. ;
Winqvist, Robert .
NATURE, 2007, 446 (7133) :316-319
[8]   BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study [J].
Frank, Bernd ;
Hemminki, Kari ;
Meindl, Alfons ;
Wappenschmidt, Barbara ;
Sutter, Christian ;
Kiechle, Marion ;
Bugert, Peter ;
Schmutzler, Rita K. ;
Bartram, Claus R. ;
Burwinkel, Barbara .
BMC CANCER, 2007, 7
[9]   Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations [J].
Gonzalez, Kelly D. ;
Noltner, Katie A. ;
Buzin, Carolyn H. ;
Gu, Dongqing ;
Wen-Fong, Cindy Y. ;
Nguyen, Vu Q. ;
Han, Jennifer H. ;
Lowstuter, Katrina ;
Longmate, Jeffrey ;
Sommer, Steve S. ;
Weitzel, Jeffrey N. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1250-1256
[10]   Long-Term Reactions to Genetic Testing for BRCA1 and BRCA2 Mutations: Does Time Heal Women's Concerns? [J].
Halbert, Chanita Hughes ;
Stopfer, Jill E. ;
McDonald, Jasmine ;
Weathers, Benita ;
Collier, Aliya ;
Troxel, Andrea B. ;
Domchek, Susan .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4302-4306